Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission.

"Declarations Ethical approvalAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (LMU Munich—application numbers 17-569 and 399-09) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consentInformed written consent was obtained from all patients. Conflict of interestL.B. is an Novartis Radiopharmaceuticals GmbH employee, unrelated to this work. M.B. received speaker honoraria from GE healthcare, Roche and LMI and is an advisor of LMI. OP received speaker fees from Lundbeck, Otsuka, Takeda and Janssen. R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk. VG received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare and Novo Nordisk. Conflict of interest L.B. is an Novartis Radiopharmaceuticals GmbH employee, unrelated to this work. M.B. received speaker honoraria from GE healthcare, Roche and LMI and is an advisor of LMI. OP received speaker fees from Lundbeck, Otsuka, Takeda and Janssen. R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk. VG received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare and Novo Nordisk."

"Funding Open Access funding enabled and organized by Projekt DEAL. LB was funded by the Munich-Clinician-Scientist Program (LMU Munich). RB is supported by a Collen-Francqui Start-Up grant. VG was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028), the Schmidheiny foundation, the Fondation privée des HUG and the Velux foundation. SK received funding from the Lüneburg heritage, the Ehrmann Foundation and the Deutsche Forschungsgemeinschaft (DFG) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198) as well as research funding from CurePSP. C.P. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198). The Lüneburg Heritage and Friedrich-Baur-Stiftung have supported the work of C.P. RP is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198), the Davos Alzheimer’s Collaborative, the VERUM Foundation, the Robert-Vogel-Foundation, the German Center for Neurodegenerative Diseases (DZNE), the Sheffield National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) and the University of Cambridge – Ludwig-Maximilians-University Munich Strategic Partnership within the framework of the German Excellence Initiative and Excellence Strategy. MT received funding from the Slovenian Research Agency, Grant Number: J7-2600 and P1-0389."